Skip to content

Phase I, double-blind, randomized, placebo-controlled study investigating the safety, tolerability and concentrations of the study product KAND145 in healthy volunteers

Status
Withdrawn
Phases
Phase 1
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-503909-11-00
Acronym
KAN0008
Enrollment
80
Registered
2023-08-09
Start date
Unknown
Completion date
Unknown
Last updated
2023-08-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian cancer

Interventions

None listed

Sponsors

Kancera AB
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Countries

Finland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026